Click here to get full coverage on Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat

Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL  MarketBeat

Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Yahoo Finance

Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?  Yahoo Finance

Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman  PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Click here to get full coverage on Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis

Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers  Trefis

Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis

Click here to get full coverage on Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan

Replimune at Leerink, Jefferies investor events March 9–10  Stock Titan

Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan

Click here to get full coverage on REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView

REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress  TradingView

REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView

Click here to get full coverage on $REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82  Nasdaq

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Click here to get full coverage on REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug  Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

Click here to get full coverage on Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL  MarketBeat

Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget

Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions?  Bitget

Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget

Click here to get full coverage on REPL: Awaiting April 10 FDA decision on RP1, with strong clinical, commercial, and pipeline momentum - TradingView

REPL: Awaiting April 10 FDA decision on RP1, with strong clinical, commercial, and pipeline momentum  TradingView

REPL: Awaiting April 10 FDA decision on RP1, with strong clinical, commercial, and pipeline momentum - TradingView

Click here to get full coverage on $REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma  Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

Click here to get full coverage on Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened - MarketBeat

Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened  MarketBeat

Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened - MarketBeat

Click here to get full coverage on Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed? - Yahoo Finance

Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?  Yahoo Finance

Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on $REPL stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 10% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan

Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma  Stock Titan

Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan

Click here to get full coverage on Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat

Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL  MarketBeat

Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on $REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on $REPL stock is up 9% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 9% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman  PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Click here to get full coverage on 44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025  Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

Click here to get full coverage on Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’  Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Click here to get full coverage on Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting  Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Click here to get full coverage on Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)  Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market?  simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Click here to get full coverage on Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection  Quiver Quantitative

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative

Click here to get full coverage on Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism  simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Click here to get full coverage on REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman  PR Newswire

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

Click here to get full coverage on BMO Capital Upgrades Replimune Group (REPL) - Nasdaq

BMO Capital Upgrades Replimune Group (REPL)  Nasdaq

BMO Capital Upgrades Replimune Group (REPL) - Nasdaq

Click here to get full coverage on Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig  GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Click here to get full coverage on Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Why Is Replimune Stock (REPL) Up 105% Today?  TipRanks

Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Click here to get full coverage on Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment?  simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Click here to get full coverage on REPL Technical Analysis & Price Forecast - Intellectia AI

REPL Technical Analysis & Price Forecast  Intellectia AI

REPL Technical Analysis & Price Forecast - Intellectia AI

Click here to get full coverage on Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today  Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Click here to get full coverage on Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha

Replimune stock gains on FDA Type A meeting (REPL:NASDAQ)  Seeking Alpha

Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Replimune burns cash as April 10 RP1 FDA action date approaches - Stock Titan

Replimune burns cash as April 10 RP1 FDA action date approaches  Stock Titan

Replimune burns cash as April 10 RP1 FDA action date approaches - Stock Titan

Click here to get full coverage on Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha

Replimune: Multiple Shots On Goal But A High Risk Binary Approaches  Seeking Alpha

Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha

Click here to get full coverage on Forbion discloses 3.5% Replimune (REPL) stake in ownership filing - Stock Titan

Forbion discloses 3.5% Replimune (REPL) stake in ownership filing  Stock Titan

Forbion discloses 3.5% Replimune (REPL) stake in ownership filing - Stock Titan

Click here to get full coverage on FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection  Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

Click here to get full coverage on Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Replimune stock down after report on drug rejection (REPL)  Seeking Alpha

Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Click here to get full coverage on Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat

Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP  MarketBeat

Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat

Click here to get full coverage on Insider Sale: Chief Financial Officer of $REPL Sells 9,154 Shares - Quiver Quantitative

Insider Sale: Chief Financial Officer of $REPL Sells 9,154 Shares  Quiver Quantitative

Insider Sale: Chief Financial Officer of $REPL Sells 9,154 Shares - Quiver Quantitative

Click here to get full coverage on REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is  GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

Click here to get full coverage on Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - TradingView

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months  TradingView

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - TradingView

Click here to get full coverage on Replimune to Present at Two Upcoming Investor Conferences - ChartMill

Replimune to Present at Two Upcoming Investor Conferences  ChartMill

Replimune to Present at Two Upcoming Investor Conferences - ChartMill

Click here to get full coverage on REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman  PR Newswire

REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

Click here to get full coverage on Leerink Partners Upgrades Replimune Group (REPL) - Nasdaq

Leerink Partners Upgrades Replimune Group (REPL)  Nasdaq

Leerink Partners Upgrades Replimune Group (REPL) - Nasdaq

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

Click here to get full coverage on Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance  GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Click here to get full coverage on Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL)  Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Click here to get full coverage on REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm  Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

Click here to get full coverage on Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ)  Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on REG - Jefferies Intl Ltd Intnl Personal Fin - Form8.5 EPT/NON-RI International Personal Fin Repl - TradingView

REG - Jefferies Intl Ltd Intnl Personal Fin - Form8.5 EPT/NON-RI International Personal Fin Repl  TradingView

REG - Jefferies Intl Ltd Intnl Personal Fin - Form8.5 EPT/NON-RI International Personal Fin Repl - TradingView

Click here to get full coverage on Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more  Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Click here to get full coverage on Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Johnson Fistel, PLLP Investigates Claims on Behalf of  GlobeNewswire

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Click here to get full coverage on Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha

Replimune stock rebounds despite downgrades (REPL:NASDAQ)  Seeking Alpha

Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on JPMorgan Boosts Replimune (REPL) Price Target Amid Approval Opti - GuruFocus

JPMorgan Boosts Replimune (REPL) Price Target Amid Approval Opti  GuruFocus

JPMorgan Boosts Replimune (REPL) Price Target Amid Approval Opti - GuruFocus

Click here to get full coverage on Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman - GlobeNewswire

Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman  GlobeNewswire

Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman - GlobeNewswire

Click here to get full coverage on Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025 - Quiver Quantitative

Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025  Quiver Quantitative

Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025 - Quiver Quantitative

Click here to get full coverage on Noteworthy Monday Option Activity: UNH, REPL, CELC - Nasdaq

Noteworthy Monday Option Activity: UNH, REPL, CELC  Nasdaq

Noteworthy Monday Option Activity: UNH, REPL, CELC - Nasdaq

Click here to get full coverage on REPL Stock Up 35% after 6-Day Win Streak - Trefis

REPL Stock Up 35% after 6-Day Win Streak  Trefis

REPL Stock Up 35% after 6-Day Win Streak - Trefis

Click here to get full coverage on Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha

Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL)  Seeking Alpha

Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL)  Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra - GuruFocus

Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra  GuruFocus

Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra - GuruFocus

Click here to get full coverage on Notable Monday Option Activity: TTD, REPL, UPST - Nasdaq

Notable Monday Option Activity: TTD, REPL, UPST  Nasdaq

REPL

Price Chart

Key Statistics

Technicals

About REPL

Latest News

Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat

Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Yahoo Finance

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Advanced Charts

Top Gainers

Top Losers